IPP Bureau
Akums Drugs enters into license and distribution agreement with Triple Hair, Canada
By IPP Bureau - October 16, 2024
Akums Drugs will undertake this development and commercialization in India
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
By IPP Bureau - October 16, 2024
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Granules India appoints Ramraj Rangarajulu as President and Head - Formulations Operations
By IPP Bureau - October 15, 2024
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Lyka’s patent pending Drug Pregabalin Gel 8% w/w receives approval from CDSCO
By IPP Bureau - October 15, 2024
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Suven Pharma appoints Declan Ryan as CCO
By IPP Bureau - October 15, 2024
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
CDSCO, NRAI meets WHO international standards for vaccine regulations
By IPP Bureau - October 14, 2024
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Indian Stroke Association launches the Bangalore chapter of ‘Mission Brain Attack’
By IPP Bureau - October 14, 2024
Strokes are affecting approximately 1.8 million people annually
Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3
By IPP Bureau - October 14, 2024
Indoco is comprehensively working on the remedial action plan
Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP
By IPP Bureau - October 14, 2024
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease
By IPP Bureau - October 14, 2024
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
AGC Biologics begins operations at new manufacturing building in Copenhagen
By IPP Bureau - October 14, 2024
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
Natac receives GMP certificate to manufacture for the pharmaceutical sector
By IPP Bureau - October 12, 2024
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Akums launches dual action heartburn relief chewable tablet
By IPP Bureau - October 12, 2024
This product is categorized as antacids, antiflatulents and anti-Ulcerants
USFDA approves Pfizer’s marstacimab-hncq for treatment of hemophilia A or B
By IPP Bureau - October 12, 2024
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
SIBUR to provide raw materials to Russian medical industry
By IPP Bureau - October 12, 2024
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
